IRWD - Ironwood Pharmaceuticals Inc

Strong Sell Momentum: Bearish

Recent News

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks Commentary • 3 weeks, 4 days ago • score: 0.32

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Neutral

IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates

Zacks Commentary • 1 month, 1 week ago • score: -0.03

Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.

52W High

$5.13

52W Low

$0.53

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.33

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

12.33

EV/EBITDA (<8 favorable)

8.71

EV/Revenue (<3 favorable)

2.25

P/S (TTM) (<3 favorable)

0.61

P/B (<3 favorable)

2.59

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.66%

Institutions (25–75% balanced)

97.98%

Shares Outstanding

162,434,000

Float

118,090,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

308,519,000

Gross Profit (TTM)

306,365,000

EPS (TTM)

-0.05

Profit Margin (>10% good)

-0.03%

Operating Margin (TTM) (higher better)

0.53%

ROE (TTM) (>15% strong)

-5.75%

EPS YoY (Quarterly) (>10% good)

-0.77

Revenue YoY (Quarterly) (>8% good)

-0.10

Momentum

Bearish momentum

Value

0.1030

0.1177

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025